STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1/Abstract	Abstract/paragraph 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1/ Abstract	Abstract/ paragraph 1-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 2/ Line 1-66	Introduction part/ Paragraph 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 2/ Line 60-66	Introduction/ Paragraph 4
Methods				
Study design	4	Present key elements of study design early in the paper	Page 2-3 /Line 68-109	Study design and
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 2 /Line 72-87; Page 3/Line 184-186	Study design and participants/ Paragraph 1;
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 2 /Line 72-87; Page 2-3/ Line 95-109; Page 3/Line 184-186	Study design and participants/Paragraph 1; Grouping/ Paragraph 1; Outcomes/ Paragraph 1.
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Not matched study	Not matched study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 3-4/Line 186-189 Page 2-3/Line 96-99	Outcomes/ Paragraph 1; Grouping/ Paragraph 1;
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page3-4/Line99-103 and Line113-114;	Grouping/ Paragraph 1; Genomic analysis/
Bias	9	Describe any efforts to address potential sources of bias	Page 3/ Line 80-84;	Study design and
Study size	10	Explain how the study size was arrived at	Page 2/Line 72-76	Study design and
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Not available, quantitative variable was not our main	Not available, quantitative variable was not our main

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	page 4 /Line 193-201	Statistical analysis/
		(b) Describe any methods used to examine subgroups and interactions	page 4 /Line 199-201	Statistical analysis/
		(c) Explain how missing data were addressed	Page 2/Line 84-85	Study design and
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Page 3 /Line 184	Study design and participants/ Paragraph 1
		(e) Describe any sensitivity analyses	Page 4/ Line 261-266	Effects of EGFR
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure1	Figure1
		(b) Give reasons for non-participation at each stage	Figure1	Figure1
		(c) Consider use of a flow diagram	Figure 1	Figure1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 4/Line 207-229;	Clinical characteristics of the study participants /
		(b) Indicate number of participants with missing data for each variable of interest	Page 4/ Line 213; Figure1	Clinical characteristics of
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 4/ Line 184-186	Outcomes/ Paragraph 1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Figure 2-6	Figure 2-6
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	Not case-control study	Not case-control study
		Cross-sectional study—Report numbers of outcome events or summary measures	Not cross-sectional study	Not cross-sectional study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 1 and Table S1-S3; There was no adjusted	Table 1 and Table S1-S3; There was no adjusted
		(b) Report category boundaries when continuous variables were categorized	There were no categorical	There were no categorical
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	No relative risk	No relative risk
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 4/ Line 249-261, Fig	Effects of EGFR
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 6/ Line 287-295	Discussion/ Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 9/ Line 275-283	Discussion/ Paragraph 6

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 9/ Line 384-391	Discussion/ Paragraph 7 and 8
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 9/ Line 380-381	Discussion/ Paragraph 6
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 1/Contributions; Page 10/ Line 397-405	Contributions; Acknowledgments/

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.